ClinicalTrials.gg

Program

HRS-2129

A development code. Also written as “HRS-2129 Tablet” and “HRS-2129 Tablets”.

In Jiangsu HengRui Medicine's pipeline, Nav1.8. Its studies are mostly in Pain · Osteoarthritis, Knee · Arthritis, Gouty · Pain, Postoperative · Neuralgia, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Sep 15, 20257 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine72 open or runningphase 3since Sep 15, 2025Sep 23, 2024none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-2129, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 23, 2024First study: phase 1 study in PainFirst studyNCT06619392 · 44 enrolled · China
  2. Dec 16, 2024Phase 1 study in PainNCT06742840 · 23 enrolled · China
  3. Jan 13, 2025Phase 2 study in Postoperative Pain in OrthopaedicsNCT06780267 · 199 enrolled · China
  4. Sep 15, 2025Phase 3 study in Postoperative AnalgesiaNCT07185594 · 156 enrolled · China
  5. Jan 11, 20262 phase 1 studiesNCT07351968, NCT07377721
  6. Jul 7, 2026Phase 2 study in Acute Gouty ArthritisNCT07706777 · 90 planned · China

TargetBeta

“Nav1.8”the company's pipeline, read by Claude · source

Other programs on SCN10A

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37
LY4515100Eli Lillyphase 23

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07706777Acute Gouty Arthritis · China2RecruitingOct 202690
NCT07377721Diabetic Peripheral Neuropathic Pain · China1RecruitingSep 2026168
NCT07351968Moderate Pain in Knee Osteoarthritis · China1CompletedJul 17, 2026202
NCT07185594Postoperative Analgesia · China3CompletedDec 31, 2025156
NCT06780267Postoperative Pain in Orthopaedics · China2CompletedMar 19, 2026199
NCT06742840Pain · China1CompletedJul 2, 202523
NCT06619392Pain · China1CompletedJan 20, 202544

How it is read

Names in the registry

  • “HRS-2129 Tablet”, 3 entries
  • “HRS-2129”, 3 entries
  • “HRS-2129 Tablets”, 2 entries

Codes read as this program: HRS2129.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.